# Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

> **NCT00054977** · PHASE1 · COMPLETED · sponsor: **Galectin Therapeutics Inc.** · enrollment: 40 (actual)

## Conditions studied

- Colorectal Cancer
- Lung Cancer
- Breast Cancer
- Head and Neck Cancer
- Prostate Cancer

## Interventions

- **DRUG:** GM-CT-01
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT00054977
- **Lead sponsor:** Galectin Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-04
- **Final completion:** 2006-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054977, "Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00054977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*